Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Stability of SARS-CoV-2 RNA in Nonsupplemented Saliva.
Ott IM, Strine MS, Watkins AE, Boot M, Kalinich CC, Harden CA, Vogels CBF, Casanovas-Massana A, Moore AJ, Muenker MC, Nakahata M, Tokuyama M, Nelson A, Fournier J, Bermejo S, Campbell M, Datta R, Dela Cruz CS, Farhadian SF, Ko AI, Iwasaki A, Grubaugh ND, Wilen CB, Wyllie AL; Yale IMPACT Research team3. Ott IM, et al. Emerg Infect Dis. 2021 Apr;27(4):1146-1150. doi: 10.3201/eid2704.204199. Emerg Infect Dis. 2021. PMID: 33754989 Free PMC article.
Increased SARS-CoV-2 Testing Capacity with Pooled Saliva Samples.
Watkins AE, Fenichel EP, Weinberger DM, Vogels CBF, Brackney DE, Casanovas-Massana A, Campbell M, Fournier J, Bermejo S, Datta R, Dela Cruz CS, Farhadian SF, Iwasaki A, Ko AI, Grubaugh ND, Wyllie AL; Yale IMPACT Research Team2. Watkins AE, et al. Emerg Infect Dis. 2021 Apr;27(4):1184-7. doi: 10.3201/eid2704.204200. Emerg Infect Dis. 2021. PMID: 33755009 Free PMC article.
De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: A case report.
Gandhi S, Klein J, Robertson A, Peña-Hernández MA, Lin MJ, Roychoudhury P, Lu P, Fournier J, Ferguson D, Mohamed Bakhash SA, Catherine Muenker M, Srivathsan A, Wunder EA, Kerantzas N, Wang W, Lindenbach B, Pyle A, Wilen CB, Ogbuagu O, Greninger AL, Iwasaki A, Schulz WL, Ko AI. Gandhi S, et al. medRxiv [Preprint]. 2021 Dec 7:2021.11.08.21266069. doi: 10.1101/2021.11.08.21266069. medRxiv. 2021. PMID: 34909781 Free PMC article. Updated. Preprint.
De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report.
Gandhi S, Klein J, Robertson AJ, Peña-Hernández MA, Lin MJ, Roychoudhury P, Lu P, Fournier J, Ferguson D, Mohamed Bakhash SAK, Catherine Muenker M, Srivathsan A, Wunder EA Jr, Kerantzas N, Wang W, Lindenbach B, Pyle A, Wilen CB, Ogbuagu O, Greninger AL, Iwasaki A, Schulz WL, Ko AI. Gandhi S, et al. Nat Commun. 2022 Mar 17;13(1):1547. doi: 10.1038/s41467-022-29104-y. Nat Commun. 2022. PMID: 35301314 Free PMC article.
Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19.
Farhadian S, Glick LR, Vogels CBF, Thomas J, Chiarella J, Casanovas-Massana A, Zhou J, Odio C, Vijayakumar P, Geng B, Fournier J, Bermejo S, Fauver JR, Alpert T, Wyllie AL, Turcotte C, Steinle M, Paczkowski P, Dela Cruz C, Wilen C, Ko AI, MacKay S, Grubaugh ND, Spudich S, Barakat LA. Farhadian S, et al. BMC Neurol. 2020 Jun 18;20(1):248. doi: 10.1186/s12883-020-01812-2. BMC Neurol. 2020. PMID: 32552792 Free PMC article.
Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19.
Farhadian S, Glick LR, Vogels CBF, Thomas J, Chiarella J, Casanovas-Massana A, Zhou J, Odio C, Vijayakumar P, Geng B, Fournier J, Bermejo S, Fauver JR, Alpert T, Wyllie AL, Turcotte C, Steinle M, Paczkowski P, Cruz CD, Wilen C, Ko AI, MacKay S, Grubaugh ND, Spudich S, Aoun Barakat L. Farhadian S, et al. Res Sq [Preprint]. 2020 May 12:rs.3.rs-28583. doi: 10.21203/rs.3.rs-28583/v1. Res Sq. 2020. PMID: 32702723 Free PMC article. Updated. Preprint.
High-resolution epitope mapping and characterization of SARS-CoV-2 antibodies in large cohorts of subjects with COVID-19.
Haynes WA, Kamath K, Bozekowski J, Baum-Jones E, Campbell M, Casanovas-Massana A, Daugherty PS, Dela Cruz CS, Dhal A, Farhadian SF, Fitzgibbons L, Fournier J, Jhatro M, Jordan G, Klein J, Lucas C, Kessler D, Luchsinger LL, Martinez B, Catherine Muenker M, Pischel L, Reifert J, Sawyer JR, Waitz R, Wunder EA Jr, Zhang M; Yale IMPACT Team; Iwasaki A, Ko A, Shon JC. Haynes WA, et al. Commun Biol. 2021 Nov 22;4(1):1317. doi: 10.1038/s42003-021-02835-2. Commun Biol. 2021. PMID: 34811480 Free PMC article.
Phenotypes of disease severity in a cohort of hospitalized COVID-19 patients: Results from the IMPACC study.
Ozonoff A, Schaenman J, Jayavelu ND, Milliren CE, Calfee CS, Cairns CB, Kraft M, Baden LR, Shaw AC, Krammer F, van Bakel H, Esserman DA, Liu S, Sesma AF, Simon V, Hafler DA, Montgomery RR, Kleinstein SH, Levy O, Bime C, Haddad EK, Erle DJ, Pulendran B, Nadeau KC, Davis MM, Hough CL, Messer WB, Higuita NIA, Metcalf JP, Atkinson MA, Brakenridge SC, Corry D, Kheradmand F, Ehrlich LIR, Melamed E, McComsey GA, Sekaly R, Diray-Arce J, Peters B, Augustine AD, Reed EF, Altman MC, Becker PM, Rouphael N; IMPACC study group members. Ozonoff A, et al. EBioMedicine. 2022 Sep;83:104208. doi: 10.1016/j.ebiom.2022.104208. Epub 2022 Aug 8. EBioMedicine. 2022. PMID: 35952496 Free PMC article.
An AI-powered patient triage platform for future viral outbreaks using COVID-19 as a disease model.
Charkoftaki G, Aalizadeh R, Santos-Neto A, Tan WY, Davidson EA, Nikolopoulou V, Wang Y, Thompson B, Furnary T, Chen Y, Wunder EA, Coppi A, Schulz W, Iwasaki A, Pierce RW, Cruz CSD, Desir GV, Kaminski N, Farhadian S, Veselkov K, Datta R, Campbell M, Thomaidis NS, Ko AI; Yale IMPACT Study Team; Thompson DC, Vasiliou V. Charkoftaki G, et al. Hum Genomics. 2023 Aug 29;17(1):80. doi: 10.1186/s40246-023-00521-4. Hum Genomics. 2023. PMID: 37641126 Free PMC article.
109 results